211 related articles for article (PubMed ID: 26196464)
1. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
2. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
3. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
4. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
5. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
[TBL] [Abstract][Full Text] [Related]
7. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.
Xie Z; Gunaratne J; Cheong LL; Liu SC; Koh TL; Huang G; Blackstock WP; Chng WJ
Oncotarget; 2013 Jul; 4(7):1008-18. PubMed ID: 23900284
[TBL] [Abstract][Full Text] [Related]
8. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
[TBL] [Abstract][Full Text] [Related]
9. Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma.
Todoerti K; Ronchetti D; Agnelli L; Castellani S; Marelli S; Deliliers GL; Zanella A; Lombardi L; Neri A
Br J Haematol; 2005 Oct; 131(2):214-8. PubMed ID: 16197452
[TBL] [Abstract][Full Text] [Related]
10. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
[TBL] [Abstract][Full Text] [Related]
11. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
12. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
13. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
14. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.
Tang S; Zhang F; Li J; Dong H; Yang Q; Liu J; Fu Y
Chem Biol Interact; 2023 Oct; 384():110687. PubMed ID: 37657595
[TBL] [Abstract][Full Text] [Related]
15. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
White-Al Habeeb NM; Garcia J; Fleshner N; Bapat B
Prostate; 2016 Dec; 76(16):1507-1518. PubMed ID: 27404348
[TBL] [Abstract][Full Text] [Related]
16. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
17. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
Marango J; Shimoyama M; Nishio H; Meyer JA; Min DJ; Sirulnik A; Martinez-Martinez Y; Chesi M; Bergsagel PL; Zhou MM; Waxman S; Leibovitch BA; Walsh MJ; Licht JD
Blood; 2008 Mar; 111(6):3145-54. PubMed ID: 18156491
[TBL] [Abstract][Full Text] [Related]
18. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
[TBL] [Abstract][Full Text] [Related]
19. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
[TBL] [Abstract][Full Text] [Related]
20. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
Stewart JP; Thompson A; Santra M; Barlogie B; Lappin TR; Shaughnessy J
Br J Haematol; 2004 Jul; 126(1):72-6. PubMed ID: 15198734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]